表紙
市場調查報告書

醫療相關感染疾病診斷的全球市場的分析與預測 - 各產品/服務、疾病的各類型、各終端用戶 (到2025年):新型冠狀病毒感染疾病 (COVID-19)的累積影響

Healthcare-associated Infectious Disease Diagnostics Market Research Report by Product & Service, by Disease Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 967938
出版日期 內容資訊 英文 157 Pages
商品交期: 最快1-2個工作天內
價格
醫療相關感染疾病診斷的全球市場的分析與預測 - 各產品/服務、疾病的各類型、各終端用戶 (到2025年):新型冠狀病毒感染疾病 (COVID-19)的累積影響 Healthcare-associated Infectious Disease Diagnostics Market Research Report by Product & Service, by Disease Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19
出版日期: 2020年10月22日內容資訊: 英文 157 Pages
簡介

全球醫療相關感染疾病診斷的市場規模,預計從2019年的29億9353萬美元,到2025年終達45億6772萬美元,以7.29%的年複合成長率成長。

本報告提供全球醫療相關感染 (HAI) 診斷的市場相關分析,市場最新趨勢和促進、阻礙因素,整體市場規模趨勢預測,各產品/服務、疾病的各類型、各終端用戶及各地區、主要國家詳細趨勢,市場佔有率結構和最新的市場競爭趨勢,主要企業的簡介,新型冠狀病毒感染疾病 (COVID-19) 的到目前為止的累積的影響等資訊彙整,為您概述為以下內容。

目錄

第1章 序論

第2章 調查手法

第3章 摘要整理

第4章 市場概要

第5章 市場動態

  • 簡介
  • 促進因素
    • 重點的轉變:從集中型檢驗室到分散式、PoC檢驗
    • 感染疾病診斷的研究資金的增額
  • 阻礙因素
    • 為了防止在醫療現場的HAI (醫療相關感染) 的嚴格法規
    • 可控制HAI的先進機制
  • 市場機會
    • 醫療相關感染疾病的對象患者的增加
    • 低、中所得國的高成長可能性
    • 為了診斷HAI的PoC (照護現場) 檢驗的滲透
  • 課題
    • 不完全的醫療費償付
    • 高所得國的HAI的盛行率低

第6章 市場考察

  • 波特的五力分析
  • COVID-19累積的影響
  • 客戶的客製化

第7章 全球醫療相關感染疾病診斷市場:各產品/服務

  • 簡介
  • 化驗、套件、試劑
  • 診斷設備
  • 服務、軟體

第8章 全球醫療相關感染疾病診斷市場:疾病的各類型

  • 簡介
  • 披衣菌感染、淋病
  • 肝炎
  • 院內感染
  • 人免疫力缺乏病毒 (HIV)
  • 人類乳突病毒
  • 流感
  • 結核

第9章 全球醫療相關感染疾病診斷市場:各終端用戶

  • 簡介
  • 教育/研究機關
  • 醫院/臨床檢驗室
  • 開業醫生
  • 參考檢驗室

第10章 南北美洲的醫療相關感染疾病診斷市場

  • 簡介
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區的醫療相關感染疾病診斷市場

  • 簡介
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第12章 歐洲、中東、非洲的醫療相關感染疾病診斷市場

  • 簡介
  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國 (UAE)
  • 英國

第13章 競爭情形

  • FPNV定位、矩陣
    • 市場區隔
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 競爭模式
    • 企業合併、收購 (M&A)
    • 協定,事業合作、聯盟
    • 新產品的銷售與改良
    • 投資、資金籌措
    • 獲獎、認證、擴張

第14章 企業的實用性、簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Co-Diagnostics Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • DNAe Group Holdings Ltd
  • GNA Biosolutions GmbH
  • Luminex Corporation
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Roche Holding AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

第15章 附錄

目錄
Product Code: MRR-67AA438

Title:
Healthcare-associated Infectious Disease Diagnostics Market Research Report by Product & Service (Assays, Kits, & Reagents, Instruments, and Services & Software), by Disease Type (Chlamydia Trachomatis Genital Infection and Gonorrhea, Hepatitis, Hospital-Acquired Infections, Human Immunodeficiency Virus, and Human Papillomavirus), by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19.

The Global Healthcare-associated Infectious Disease Diagnostics Market is expected to grow from USD 2,993.53 Million in 2019 to USD 4,567.72 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.29%.

Market Segmentation & Coverage:

This research report categorizes the Healthcare-associated Infectious Disease Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Product & Service, the Healthcare-associated Infectious Disease Diagnostics Market studied across Assays, Kits, & Reagents, Instruments, and Services & Software.
  • Based on Disease Type, the Healthcare-associated Infectious Disease Diagnostics Market studied across Chlamydia Trachomatis Genital Infection and Gonorrhea, Hepatitis, Hospital-Acquired Infections, Human Immunodeficiency Virus, Human Papillomavirus, Influenza, and Tuberculosis.
  • Based on End-user, the Healthcare-associated Infectious Disease Diagnostics Market studied across Academic/Research Institutes, Hospital/Clinical Laboratories, Physician Offices, and Reference Laboratories.
  • Based on Geography, the Healthcare-associated Infectious Disease Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Healthcare-associated Infectious Disease Diagnostics Market including Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Co-Diagnostics Inc., Danaher Corporation, DiaSorin S.p.A., DNAe Group Holdings Ltd, GNA Biosolutions GmbH, Luminex Corporation, Meridian Bioscience Inc., Quidel Corporation, Roche Holding AG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Healthcare-associated Infectious Disease Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Healthcare-associated Infectious Disease Diagnostics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Healthcare-associated Infectious Disease Diagnostics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Healthcare-associated Infectious Disease Diagnostics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Healthcare-associated Infectious Disease Diagnostics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Healthcare-associated Infectious Disease Diagnostics Market?
  • 6. What are the modes and strategic moves considered suitable for entering the Global Healthcare-associated Infectious Disease Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Product & Service Outlook
  • 3.4. End-user Outlook
  • 3.5. Disease Type Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

  • 4.1. Introduction

5. Market Dynamics

  • 5.1. Introduction
  • 5.2. Drivers
    • 5.2.1. Shift in focus from centralized laboratories to decentralized point-of-care testing
    • 5.2.2. Shift in focus from centralized laboratories to decentralized point-of-care testing
    • 5.2.3. Growth in funding for research on infectious disease diagnostics
  • 5.3. Restraints
    • 5.3.1. Stringent regulations to prevent HAIs in healthcare settings
    • 5.3.2. Sophisticated mechanisms available to control HAIs
  • 5.4. Opportunities
    • 5.4.1. Increase in target patients with healthcare-associated infections
    • 5.4.2. High growth potential in low and middle-income countries
    • 5.4.3. Growing penetration of POC tests to diagnose HAIs
  • 5.5. Challenges
    • 5.5.1. Inadequate reimbursements
    • 5.5.2. Low prevalence of HAIs in high-income nations

6. Market Insights

  • 6.1. Porters Five Forces Analysis
    • 6.1.1. Threat of New Entrants
    • 6.1.2. Threat of Substitutes
    • 6.1.3. Bargaining Power of Customers
    • 6.1.4. Bargaining Power of Suppliers
    • 6.1.5. Industry Rivalry
  • 6.2. Cumulative Impact of COVID-19
  • 6.3. Client Customizations

7. Global Healthcare-associated Infectious Disease Diagnostics Market, By Product & Service

  • 7.1. Introduction
  • 7.2. Assays, Kits, & Reagents
  • 7.3. Instruments
  • 7.4. Services & Software

8. Global Healthcare-associated Infectious Disease Diagnostics Market, By Disease Type

  • 8.1. Introduction
  • 8.2. Chlamydia Trachomatis Genital Infection and Gonorrhea
  • 8.3. Hepatitis
  • 8.4. Hospital-Acquired Infections
  • 8.5. Human Immunodeficiency Virus
  • 8.6. Human Papillomavirus
  • 8.7. Influenza
  • 8.8. Tuberculosis

9. Global Healthcare-associated Infectious Disease Diagnostics Market, By End-user

  • 9.1. Introduction
  • 9.2. Academic/Research Institutes
  • 9.3. Hospital/Clinical Laboratories
  • 9.4. Physician Offices
  • 9.5. Reference Laboratories

10. Americas Healthcare-associated Infectious Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. South Korea
  • 11.10. Thailand

12. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis
  • 13.4. Competitive Scenario
    • 13.4.1. Merger & Acquisition
    • 13.4.2. Agreement, Collaboration, & Partnership
    • 13.4.3. New Product Launch & Enhancement
    • 13.4.4. Investment & Funding
    • 13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. Abbott Laboratories
  • 14.2. Becton, Dickinson and Company
  • 14.3. Bio-Rad Laboratories, Inc.
  • 14.4. Biomerieux SA
  • 14.5. Co-Diagnostics Inc.
  • 14.6. Danaher Corporation
  • 14.7. DiaSorin S.p.A.
  • 14.8. DNAe Group Holdings Ltd
  • 14.9. GNA Biosolutions GmbH
  • 14.10. Luminex Corporation
  • 14.11. Meridian Bioscience Inc.
  • 14.12. Quidel Corporation
  • 14.13. Roche Holding AG
  • 14.14. Siemens Healthineers AG
  • 14.15. Thermo Fisher Scientific Inc.

15. Appendix

  • 15.1. Discussion Guide

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2019 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2019 VS 2025 (USD MILLION)
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2019 VS 2025 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2019 VS 2025 (USD MILLION)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2017-2025 (USD MILLION)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: MARKET DYNAMICS
  • FIGURE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2019 VS 2025 (%)
  • FIGURE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2019 VS 2025 (USD MILLION)
  • FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2025
  • FIGURE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAYS, KITS, & REAGENTS, 2019 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2019 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERVICES & SOFTWARE, 2019 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2019 VS 2025 (%)
  • FIGURE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2019 VS 2025 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025
  • FIGURE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS GENITAL INFECTION AND GONORRHEA, 2019 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2019 VS 2025 (USD MILLION)
  • FIGURE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL-ACQUIRED INFECTIONS, 2019 VS 2025 (USD MILLION)
  • FIGURE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, 2019 VS 2025 (USD MILLION)
  • FIGURE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, 2019 VS 2025 (USD MILLION)
  • FIGURE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA, 2019 VS 2025 (USD MILLION)
  • FIGURE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, 2019 VS 2025 (USD MILLION)
  • FIGURE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2019 VS 2025 (%)
  • FIGURE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2019 VS 2025 (USD MILLION)
  • FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025
  • FIGURE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC/RESEARCH INSTITUTES, 2019 VS 2025 (USD MILLION)
  • FIGURE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL/CLINICAL LABORATORIES, 2019 VS 2025 (USD MILLION)
  • FIGURE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, 2019 VS 2025 (USD MILLION)
  • FIGURE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, 2019 VS 2025 (USD MILLION)
  • FIGURE 37. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
  • FIGURE 38. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 40. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 41. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 42. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 43. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 44. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 45. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
  • FIGURE 46. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  • FIGURE 47. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 48. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 49. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 50. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 51. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 52. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 53. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 54. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 55. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 56. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 57. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
  • FIGURE 58. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  • FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 60. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 61. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 62. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 63. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 64. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 65. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 66. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 67. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 68. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 69. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 70. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • FIGURE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
  • FIGURE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
  • FIGURE 73. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2017-2025 (USD MILLION)
  • TABLE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAYS, KITS, & REAGENTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERVICES & SOFTWARE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS GENITAL INFECTION AND GONORRHEA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL-ACQUIRED INFECTIONS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC/RESEARCH INSTITUTES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL/CLINICAL LABORATORIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 20. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 21. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 22. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 23. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 24. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 25. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 26. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 27. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 28. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 29. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 30. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 31. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 32. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 33. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 34. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 35. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 36. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 37. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 38. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 43. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 44. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 45. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 46. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 47. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 48. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 49. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 50. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 51. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 52. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 53. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 54. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 55. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 56. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 57. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 58. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 59. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 60. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 61. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 62. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 63. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 64. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 65. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 66. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 67. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 68. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 69. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 74. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 75. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 76. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 77. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 78. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 79. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 80. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 81. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 82. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 83. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 84. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 85. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 86. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 87. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 88. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 89. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 90. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 91. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 92. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 93. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 94. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 95. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 96. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 97. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 98. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 99. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 100. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 104. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 105. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2025 (USD MILLION)
  • TABLE 106. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2017-2025 (USD MILLION)
  • TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: SCORES
  • TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: BUSINESS STRATEGY
  • TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT SATISFACTION
  • TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RANKING
  • TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: MERGER & ACQUISITION
  • TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: INVESTMENT & FUNDING
  • TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION